These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33228171)

  • 1. The Role of the T2-FLAIR Mismatch Sign as an Imaging Marker of IDH Status in a Mixed Population of Low- and High-Grade Gliomas.
    Kapsalaki EZ; Brotis AG; Tsikrika A; Tzerefos C; Paschalis T; Dardiotis E; Fountas KN
    Brain Sci; 2020 Nov; 10(11):. PubMed ID: 33228171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
    Foltyn M; Nieto Taborda KN; Neuberger U; Brugnara G; Reinhardt A; Stichel D; Heiland S; Herold-Mende C; Unterberg A; Debus J; von Deimling A; Wick W; Bendszus M; Kickingereder P
    Neurooncol Adv; 2020; 2(1):vdaa004. PubMed ID: 32642675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
    Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
    Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
    Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
    Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
    Park SI; Suh CH; Guenette JP; Huang RY; Kim HS
    Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
    Patel SH; Poisson LM; Brat DJ; Zhou Y; Cooper L; Snuderl M; Thomas C; Franceschi AM; Griffith B; Flanders AE; Golfinos JG; Chi AS; Jain R
    Clin Cancer Res; 2017 Oct; 23(20):6078-6085. PubMed ID: 28751449
    [No Abstract]   [Full Text] [Related]  

  • 11. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
    Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
    J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.
    Yamashita S; Takeshima H; Kadota Y; Azuma M; Fukushima T; Ogasawara N; Kawano T; Tamura M; Muta J; Saito K; Takeishi G; Mizuguchi A; Watanabe T; Ohta H; Yokogami K
    Brain Tumor Pathol; 2022 Apr; 39(2):88-98. PubMed ID: 35482260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
    Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
    AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
    Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
    Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric-type diffuse low-grade glioma with T2-FLAIR mismatch sign: a case report and literature review.
    Hwa JC; Wong AM; Jung SM; Wu CT
    Childs Nerv Syst; 2024 Aug; 40(8):2271-2278. PubMed ID: 38884778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of IDH-mutated gliomas.
    Zang Y; Feng L; Zheng F; Shi X; Chen X
    Clin Neurol Neurosurg; 2024 Nov; 246():108579. PubMed ID: 39395280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Yamamoto H; Iwaki T; Hiwatashi A; Ishigami K
    Sci Rep; 2022 Jun; 12(1):9197. PubMed ID: 35654812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of synthetic MRI for differentiation of IDH-mutant diffuse gliomas and its comparison with the T2-FLAIR mismatch sign.
    Onishi S; Yamasaki F; Akiyama Y; Kawahara D; Amatya VJ; Yonezawa U; Taguchi A; Ozono I; Khairunnisa NI; Takeshima Y; Horie N
    J Neurooncol; 2024 Nov; 170(2):429-436. PubMed ID: 39133381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.
    Lee MD; Jain R; Galbraith K; Chen A; Lieberman E; Patel SH; Placantonakis DG; Zagzag D; Barbaro M; Guillermo Prieto Eibl MDP; Golfinos JG; Orringer DA; Snuderl M
    Clin Cancer Res; 2024 Aug; 30(16):3512-3519. PubMed ID: 38829583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.